NasdaqHealth CarePharmaceutical PreparationsTAMPA, FL

Akari Therapeutics Plc AKTX

Ask your AI

ADR: the number of shares per ADR isn’t known yetCIK 1541157

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

3 added · 1 trimmed

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Akari Therapeutics Plc's latest quarterly report, compared with the one before.

Filed Nov 12, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Akari Therapeutics Plc's latest quarterly report, compared with the one before.

Loading…

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Aug 25, 2025. Insiders have two business days to file.

Recent insider trades

Abizer Gaslightwala CEO, Director	Aug 25, 2025 Form 4 ↗	Buy	+$2,700 3,000 sh @ $0.90	-98.2%
Abizer Gaslightwala CEO, Director	Aug 22, 2025 Form 4 ↗	Buy	+$7,440 8,000 sh @ $0.93	-98.5%
Abizer Gaslightwala CEO, Director	Aug 21, 2025 Form 4 ↗	Buy	+$9,400 10,000 sh @ $0.94	-100.3%
Abizer Gaslightwala President & CEO, Director	Jun 24, 2025 Form 4 ↗	Buy	+$6,035 5,203 sh @ $1.16	-109.7%
Abizer Gaslightwala President & CEO, Director	Jun 23, 2025 Form 4 ↗	Buy	+$1,084 943 sh @ $1.15	-111.0%

All AKTX insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

52,912 shares

7 funds report AKTX. Values checked against market prices.

Q3 2026. 2 new, 3 added to, 1 trimmed, 3 exited since Q2 2026.

Top 13F holders
#
1	Jane Street Group, LLC 13F ↗	23,242	$216.2K	+50.3%
2	Occidental Asset Management, LLC 13F ↗	18,125	$168.6K	New
3	Mmcap International Inc. SPC 13F ↗	11,427	$106.3K	-88.6%
4	Nuveen, LLC 13F ↗	86	$836	New
5	SBI Securities Co., Ltd. 13F ↗	15	$140	+7.1%
6	Caitong International Asset Management Co., Ltd 13F ↗	10	$93	+25.0%
7	Northwestern Mutual Wealth Management Co 13F ↗	7	$65	unchanged

Download CSV Every fund that holds AKTX, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Akari Therapeutics Plc and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Akari Therapeutics Plc and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2026	6	—	59,671	$307.3K
Q2 2026	9	+3	149,980	$1.5M
Q3 2026	7	-2	52,912	$492.1K

Each point is a quarter-end, from Q1 2026 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (00972G405). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2026) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes8 in 12 mo 8-K events3 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive pay2 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials0 active IPO history9 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Akari Therapeutics Plc
Address: 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FL 33602
Phone: (929) 274-7510
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: United Kingdom
Listed as: AKTX (Nasdaq)
Former names: Celsus Therapeutics Plc. (until 2015); Morria Biopharmaceuticals PLC (until 2013)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$6.80+$0.29 (+4.45%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $6.51 · High $9.89Nov 13, 2026

Aug 13, 2026Low $6.51 · High $11.47Nov 13, 2026

Nov 13, 2025Low $3.06 · High $22.05Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. The stock split 1-for-40 on Mar 31, 2026; earlier prices are shown divided by the split ratio. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.